Clinical Trials Sponsored by Yangtze River Pharmaceutical Group Co., Ltd.

Total 518 results

Sichuan Haisco Pharmaceutical Group Co., Ltd
The First Hospital of Jilin University

Completed

Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Healthy Elderly Subjects

Healthy Elderly Subjects

China
Kaifeng Pharmaceutical (Group) Co., Ltd.
Beijing Furen Biomedical Research Institute Co., Ltd.

Unknown

A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Hemophilia A

China
Sichuan Haisco Pharmaceutical Group Co., Ltd
First Affiliated Hospital of Suzhou Medical College

Completed

Mass Balance and Biotransformation of [14C]HSK7653 in Human

Type II Diabetes

China
Sichuan Haisco Pharmaceutical Group Co., Ltd
The First Affiliated Hospital of Zhengzhou University

Completed

Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Impairment Renal Functions

Chronic Renal Impairment

China
Azidus Brasil
Boya Bio Pharmaceutical Group Co Ltd

Not yet recruiting

Efficacy and Safety and Pharmacokinetics of Boya IVIG (Boya)

Primary Immunodeficiency Disease
Chengdu Zenitar Biomedical Technology Co., Ltd

Not yet recruiting

Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors

Myeloproliferative Neoplasm (MPN) | Myelofibrosis，MF
Tasly Pharmaceutical Group Co., Ltd
Sutro Biopharma, Inc.

Recruiting

A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors

Neoplasm Malignant

China
Korean Cancer Study Group
Boryung Pharmaceutical Co., Ltd

Unknown

Efficacy Study of Paclitaxel Versus Irinotecan in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy

Gastric Cancer

Korea, Republic of
Beijing Tiantan Hospital
Tasly Pharmaceutical Group Co., Ltd

Active, not recruiting

CerebrAlcare Pills on CereBral Small VesseL DiseasE（CABLE）

Cerebral Small Vessel Diseases

China
Korean Hemodialysis Study Group
Boryung Pharmaceutical Co., Ltd

Unknown

High Versus Standard Volume Hemodiafiltration in Asia

End-stage Renal Disease

Korea, Republic of
Sihuan Pharmaceutical Holdings Group Ltd.
Covance; XuanZhu Pharma Co., Ltd.

Completed

A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Sichuan Haisco Pharmaceutical Group Co., Ltd
Second Affiliated Hospital, School of Medicine, Zhejiang University

Completed

Safety, Tolerability and Pharmacokinetics of HSK21542 in Healthy Volunteers

Healthy Volunteers

China
Shandong University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen

Cervical Cancer | Ovarian Cancer

China
Ruijin Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer (N-PRC)

Rectal Cancer | Locally Advanced
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Recruiting

Study of APG2575 Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

Myeloid Malignancy | Relapsed/Refractory Acute Myeloid Leukaemia

China
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Recruiting

A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

EGFR Positive Non-small Cell Lung Cancer

China
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Active, not recruiting

A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

China
Tongji Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC (ALTER-L013)

NSCLC

China
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.

SLE

China
Ruijin Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001) (ALTER-G-001)

Gastrointestinal Tumors

China
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Recruiting

A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML)

China
Tongji Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Combination of ETV, TQ-A3334 and TQ-B2450 for CHB (Neptune Study) (Neptune)

Chronic Hepatitis b
Peking University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA

Gastric Cancer | Adenocarcinoma of Esophagogastric Junction

China
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Recruiting

APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors

Solid Tumor | Neuroblastoma

China
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Recruiting

APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors

Advanced Solid Tumor | Liposarcoma

China
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Recruiting

APG-2449 in Patients With Advanced Solid Tumors

Esophageal Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Malignant Pleural Mesothelioma | Advanced Solid Cancer

China
Sichuan University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer

Non-squamous Non-small-cell Lung Cancer | Anlotinib

China
Zhejiang University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients (ALTER-C-002)

Digestive System Diseases | Gastrointestinal Diseases | Neoplasms | Neoplasms by Site | Gastrointestinal Neoplasms | Digestive System Neoplasms | Colonic Diseases | Intestinal Diseases | Colorectal Neoplasms | Intestinal Neoplasms | Rectal Diseases | Colorectal Cancer | RAS and BRAF Wild-type

China
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd.

Terminated

APG-1252 in Patients With SCLC or Advanced Solid Tumors

Small Cell Lung Cancer and Other Solid Tumors

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Fudan University

Unknown

A Phase I Study of Subutinib Maleate Capsules on Toleration and Pharmacokinetics

Solid Tumor

China
Beijing Continent Pharmaceutical Co, Ltd.
Shanghai Genomics, Inc.; GNI-EPS Pharmaceuticals, Inc. (GNI Group)

Unknown

Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung Disease

Systemic Sclerosis-associated Interstitial Lung Disease (Ssc-ild)

China
Beijing Continent Pharmaceutical Co, Ltd.
Shanghai Genomics, Inc.; GNI-EPS Pharmaceuticals, Inc. (GNI Group)

Unknown

Safety and Efficacy Study of Pirfenidone to Treat Grade 2 or Above Radiation-induced Lung Injury

Radiation Pneumonitis
Shanghai Zhongshan Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors (FAITH)

Hepatocellular Carcinoma

China
Henan Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.

Esophageal Neoplasms

China
Chinese PLA General Hospital
Jiangsu Suzhong Pharmaceutical Group Co., Ltd.

Unknown

Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease

Chronic Kidney Disease

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Nanjing Medical University

Completed

A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics (ALTN)

Advanced Cancer

China
Yooyoung Pharmaceutical Co., Ltd.
Opera CRO, a TIGERMED Group Company

Not yet recruiting

Post Marketing Clinical Follow up Study to Evaluate the Performance and Safety of ORTHIX PLUS

Osteoarthritis, Knee | Degenerative Joint Disease of Knee
Yooyoung Pharmaceutical Co., Ltd.
Opera CRO, a TIGERMED Group Company

Not yet recruiting

Post Marketing Clinical Follow up Study to Evaluate the Performance and Safety of HYALEXO

Osteoarthritis | Degenerative Joint Disease
China-Japan Friendship Hospital
Guangxi Wuzhou Pharmaceutical (GROUP) Co., Ltd.

Active, not recruiting

Xueshuantong Injection (Lyophilized) in the Prevention of Venous Thromboembolism (VTE) in Hospitalized Patients

Thromboembolism | Venous Thromboembolism (VTE)

China
Henan Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.

Esophageal Squamous Cell Carcinoma

China
Henan Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLC

Non-squamous Cell Non-Small Cell Lung Cancer

China
Guizhou Bailing Group Pharmaceutical Co Ltd
China-Japan Friendship Hospital

Completed

Clinical Trials for the Optimal Dosage of Tang Ning Tongluo Capsule (TNTL)

Accidental Exposure While Preparing Drug for Administration

China
Zhejiang Cancer Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Innovent Biologics (Suzhou)...

Unknown

The Efficacy and Safety of Antinib Hydrochloride Combined With Sindilumab in Advanced NSCLC Patients

NSCLC

China
Tongji Hospital
Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC)

Recruiting

Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma (CCGLC-012)

Cholangiocarcinoma Non-resectable

China
Sun Yat-sen University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

First-line Anlotinib Combined With Penpulimab for Advanced Pheochromocytoma: A Single-arm, Multicenter, Prospective Phase II Study

Pheochromocytoma

China
Asan Medical Center
Korean Cancer Study Group; Boryung Pharmaceutical Co., Ltd

Recruiting

A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer (BRISK)

Advanced Solid Tumors | Metastatic Cancer | Solid Tumors

Korea, Republic of
Sun Yat-sen University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma (ALTER-HN005)

Nasopharyngeal Neoplasms
Beijing Tiantan Hospital
Tasly Pharmaceutical Group Co., Ltd; Beijing Neurosurgical Institute

Recruiting

Tris-CAR-T Cell Therapy for Recurrent Glioblastoma

Recurrent Glioblastoma

China
Peking Union Medical College Hospital
CSPC Ouyi Pharmaceutical Group Co., Ltd.

Not yet recruiting

Clinical Study of ABCD in the Treatment of Cryptococcal Meningitis

Cryptococcal Meningitis

China
Sun Yat-sen University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma

Soft Tissue Sarcoma

China

Clinical Trials Sponsored by Yangtze River Pharmaceutical Group Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Indonesia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations